Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ian Taylor

Showing results (121-130 of 134) with videos related to

Pageof 14
Sort By:
Proceedings of the National Academy of Sciences of the United States of America|March 4, 2009
The N-end rule pathway promotes seed germination and establishment through removal of ABA sensitivity in ArabidopsisTara J Holman, Peter D Jones, Laurel Russell, et al.
Biorxiv : the Preprint Server for Biology|February 24, 2023
Tertiary Lymphoid Structures Sustain Cutaneous B cell Activity in Hidradenitis SuppurativaMargaret M Lowe, Jarish N Cohen, Madison I Moss, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 12, 2011
Phase I dose-escalation study of the pan-HER inhibitor, PF299804, in patients with advanced malignant solid tumorsPasi A Jänne, David S Boss, D Ross Camidge, et al.
Cancer|February 7, 2014
A phase 2 trial of dacomitinib (PF-00299804), an oral, irreversible pan-HER (human epidermal growth factor receptor) inhibitor, in patients with advanced non-small cell lung cancer after failure of prior chemotherapy and erlotinibKaren L Reckamp, Giuseppe Giaccone, D Ross Camidge, et al.
JCI Insight|December 19, 2023
Tertiary lymphoid structures sustain cutaneous B cell activity in hidradenitis suppurativaMargaret M Lowe, Jarish N Cohen, Madison I Moss, et al.
Journal of the American Society of Nephrology : JASN|June 17, 2021
Progressive Cellular Senescence Mediates Renal Dysfunction in Ischemic NephropathySeo Rin Kim, Amrutesh S Puranik, Kai Jiang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 4, 2012
Randomized phase II study of dacomitinib (PF-00299804), an irreversible pan-human epidermal growth factor receptor inhibitor, versus erlotinib in patients with advanced non-small-cell lung cancerSuresh S Ramalingam, Fiona Blackhall, Maciej Krzakowski, et al.
Npj Imaging|July 3, 2025
Rapid 3D imaging at cellular resolution for digital cytopathology with a multi-camera array scanner (MCAS)Kanghyun Kim, Amey Chaware, Clare B Cook, et al.
The Lancet. Oncology|December 3, 2014
Dacomitinib versus erlotinib in patients with advanced-stage, previously treated non-small-cell lung cancer (ARCHER 1009): a randomised, double-blind, phase 3 trialSuresh S Ramalingam, Pasi A Jänne, Tony Mok, et al.
Chemistry & Biology|September 1, 2009
A Staphylococcus aureus fitness test platform for mechanism-based profiling of antibacterial compoundsRobert G K Donald, Stephen Skwish, R Allyn Forsyth, et al.
Pageof 14

Showing results (121-130 of 134) with videos related to

Sort By:
Pageof 14
Proceedings of the National Academy of Sciences of the United States of America|March 4, 2009
The N-end rule pathway promotes seed germination and establishment through removal of ABA sensitivity in ArabidopsisTara J Holman, Peter D Jones, Laurel Russell, et al.
Biorxiv : the Preprint Server for Biology|February 24, 2023
Tertiary Lymphoid Structures Sustain Cutaneous B cell Activity in Hidradenitis SuppurativaMargaret M Lowe, Jarish N Cohen, Madison I Moss, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 12, 2011
Phase I dose-escalation study of the pan-HER inhibitor, PF299804, in patients with advanced malignant solid tumorsPasi A Jänne, David S Boss, D Ross Camidge, et al.
Cancer|February 7, 2014
A phase 2 trial of dacomitinib (PF-00299804), an oral, irreversible pan-HER (human epidermal growth factor receptor) inhibitor, in patients with advanced non-small cell lung cancer after failure of prior chemotherapy and erlotinibKaren L Reckamp, Giuseppe Giaccone, D Ross Camidge, et al.
JCI Insight|December 19, 2023
Tertiary lymphoid structures sustain cutaneous B cell activity in hidradenitis suppurativaMargaret M Lowe, Jarish N Cohen, Madison I Moss, et al.
Journal of the American Society of Nephrology : JASN|June 17, 2021
Progressive Cellular Senescence Mediates Renal Dysfunction in Ischemic NephropathySeo Rin Kim, Amrutesh S Puranik, Kai Jiang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 4, 2012
Randomized phase II study of dacomitinib (PF-00299804), an irreversible pan-human epidermal growth factor receptor inhibitor, versus erlotinib in patients with advanced non-small-cell lung cancerSuresh S Ramalingam, Fiona Blackhall, Maciej Krzakowski, et al.
Npj Imaging|July 3, 2025
Rapid 3D imaging at cellular resolution for digital cytopathology with a multi-camera array scanner (MCAS)Kanghyun Kim, Amey Chaware, Clare B Cook, et al.
The Lancet. Oncology|December 3, 2014
Dacomitinib versus erlotinib in patients with advanced-stage, previously treated non-small-cell lung cancer (ARCHER 1009): a randomised, double-blind, phase 3 trialSuresh S Ramalingam, Pasi A Jänne, Tony Mok, et al.
Chemistry & Biology|September 1, 2009
A Staphylococcus aureus fitness test platform for mechanism-based profiling of antibacterial compoundsRobert G K Donald, Stephen Skwish, R Allyn Forsyth, et al.
Pageof 14